PD-L1 testing in advanced gastric cancer-what physicians who treat this disease must know-a literature review.

ABSTRACT:

Background and objective

Immune checkpoint inhibition has shed light on a new era in cancer therapy, and randomized clinical trials have demonstrated that a meaningful portion of the overall population of metastatic gastric cancer (GC) patients may derive clinical benefit from immunotherapy, which raises the relevance in identifying predictive biomarkers. Programmed cell death-ligand 1 (PD-L1) expression has demonstrated a significant association between level of expression and the magnitude of benefit derived from immune checkpoint inhibition in GC. Nevertheless, this biomarker shows several pitfalls that must be considered in the therapeutic decision to incorporate immune checkpoint inhibition as the standard of care of GC, such as spatial and temporal heterogeneity, interobserve

SUBMITTER: Peixoto RD 

PROVIDER: S-EPMC10331768 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature